Notably, clinical responses correlated with a decrease in circulating CD4+ regulatory T cells and an increase in CD4+ effector T cells, as well as with the infiltration of the tumor microenvironment by cytotoxic CD8+ T cells [97]. This evidence concerns the gene CD8A and neoplasm.